Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges

References

• WenPYKesariSMalignant gliomas in adultsN Engl J MedJul 312008359549250718669428
   PubMed Web of Science ®Google Scholar
• WrenschMMinnYChewTBondyMBergerMSEpidemiology of primary brain tumors: current concepts and review of the literatureNeuro Oncol1020024427829912356358
   PubMed Web of Science ®Google Scholar
• GiglioPVillanoJLNewly diagnosed high-grade gliomasCurr Treat Options Neurol7201012430932020842590
   PubMed Web of Science ®Google Scholar
• StuppRMasonWPvan den BentRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J MedMar 1020053521098799615758009
   PubMed Web of Science ®Google Scholar
• StuppRHegiMEGilbertMRChakravartiAChemoradiotherapy in malignant glioma: standard of care and future directionsJ Clin OncolSep 10200725264127413617827463
   PubMed Web of Science ®Google Scholar
• StuppRHegiMEMasonWPEffects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialLancet Oncol5200910545946619269895
   PubMed Web of Science ®Google Scholar
• HegiMEDiserensACGodardSClinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomideClin Cancer ResMar 1520041061871187415041700
   PubMed Web of Science ®Google Scholar
• HegiMEDiserensACGorliaTMGMT gene silencing and benefit from temozolomide in glioblastomaN Engl J MedMar 10200535210997100315758010
   PubMed Web of Science ®Google Scholar
• HegiMELiuLHermanJGCorrelation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activityJ Clin OncolSep 1200826254189419918757334
   PubMed Web of Science ®Google Scholar
• ChamberlainMCEmerging clinical principles on the use of bevacizumab for the treatment of malignant gliomasCancerMay 28
   Google Scholar
• WongETHessKRGleasonMJOutcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trialsJ Clin Oncol819991782572257810561324
   PubMed Web of Science ®Google Scholar
• FolkmanJTumor angiogensis: role in regulation of tumor growthSymp Soc Dev Biol197430043524600889
   PubMedGoogle Scholar
• FolkmanJWhat is the evidence that tumors are angiogenesis dependent?J Natl Cancer InstJan 31990821461688381
   PubMed Web of Science ®Google Scholar
• GeigerTRPeeperDSMetastasis mechanismsBiochimica et biophysica acta [Research Support, Non-U.S. Gov’t Review]1220091796229330819683560
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAThe hallmarks of cancerCellJan 720001001577010647931
   PubMed Web of Science ®Google Scholar
• BergersGBenjaminLETumorigenesis and the angiogenic switchNature reviews Cancer. [Review]6200336401410
   PubMed Web of Science ®Google Scholar
• ParikhAAEllisLMThe vascular endothelial growth factor family and its receptors. Hematology/oncology clinics of North America. Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, PHSReview102004185951971vii
   Google Scholar
• FolkmanJAngiogenesis: an organizing principle for drug discovery?Nat Rev Drug Discov420076427328617396134
   PubMed Web of Science ®Google Scholar
• JainRKNormalization of tumor vasculature: an emerging concept in antiangiogenic therapyScienceJan 720053075706586215637262
   PubMed Web of Science ®Google Scholar
• JainRKDudaDGClarkJWLoefflerJSLessons from phase III clinical trials on anti-VEGF therapy for cancerNat Clin Pract Oncol1200631244016407877
   PubMedGoogle Scholar
• CalabreseCPoppletonHKocakMA perivascular niche for brain tumor stem cellsCancer Cell12007111698217222791
   PubMed Web of Science ®Google Scholar
• BaoSWuQSathornsumeteeSStem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factorCancer ResAug 15200666167843784816912155
   PubMed Web of Science ®Google Scholar
• SiemannDWShiWTargeting the tumor blood vessel network to enhance the efficacy of radiation therapySeminars in radiation oncology. [Research Support, U.S. Gov’t, P.H.S. Review]120031315361
   Google Scholar
• MileticHNiclouSPJohanssonMBjerkvigRAnti-VEGF therapies for malignant glioma: treatment effects and escape mechanismsExpert Opin Ther Targets4200913445546819335067
   PubMed Web of Science ®Google Scholar
• LamszusKHeeseOWestphalMAngiogenesis-related growth factors in brain tumorsCancer treatment and research. [Review]2004117169190
   PubMedGoogle Scholar
• TuettenbergJFriedelCVajkoczyPAngiogenesis in malignant glioma–a target for antitumor therapy?Critical reviews in oncology/hematology. [Review]92006593181193
   Web of Science ®Google Scholar
• PrestaLGChenHO’ConnorSJChisholmVMengYGKrummenLHumanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disordersCancer researchOct 1519975720459345999377574
   PubMed Web of Science ®Google Scholar
• ZondorSDMedinaPJBevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignanciesThe Annals of pharmacotherapy. [Review]Jul-Aug2004387–812581264
   PubMed Web of Science ®Google Scholar
• DietrichJNordenADWenPYEmerging antiangiogenic treatments for gliomas—efficacy and safety issuesCurr Opin Neurol12200821673674419060566
   PubMed Web of Science ®Google Scholar
• CardonesARBanezLLVEGF inhibitors in cancer therapyCurrent pharmaceutical design. [Review]2006123387394
   PubMed Web of Science ®Google Scholar
• FerraraNHillanKJGerberHPNovotnyWDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature reviews Drug discovery. [Review]5200435391400
   PubMed Web of Science ®Google Scholar
• FerraraNHillanKJNovotnyWBevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapyBiochemical and biophysical research communications. [Review]Jul 2920053332328335
   PubMed Web of Science ®Google Scholar
• Stark-VanceVBevacizumab and CPT-11 in the treatment of relapsed malignant glioma [abstract]Neuro Oncology [Abstract]20057369
   Web of Science ®Google Scholar
• VredenburghJJDesjardinsAHerndonJE2ndBevacizumab plus irinotecan in recurrent glioblastoma multiformeJ Clin OncolOct 20200725304722472917947719
   PubMed Web of Science ®Google Scholar
• FriedmanHSPradosMDWenPYBevacizumab alone and in combination with irinotecan in recurrent glioblastomaJ Clin OncolOct 1200927284733474019720927
   PubMed Web of Science ®Google Scholar
• CloughesyTJJVBDayADasHSFriedman and for the BRAIN InvestigatorsUpdated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN studyJournal of Clinical Oncology 2010 ASCO Annual Meeting Proceedings (PostMeeting Edition). [Abstract]20102815
   Google Scholar
• KreislTNKimLMooreKPhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaJ Clin OncolFeb 10200927574074519114704
   PubMed Web of Science ®Google Scholar
• CohenMHShenYLKeeganPPazdurRFDA drug approval summary: Bevacizumab (Avastin (R)) as treatment of recurrent glioblastoma multiformeThe Oncologist20091411113119897538
   PubMed Web of Science ®Google Scholar
• BalanaCEtxanizOBugesCMartinezAApproval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?Clin Transl Oncol. [Letter]32011133209210
   Web of Science ®Google Scholar
• NarayanaAGolfinosJGFischerIFeasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade gliomaInt J Radiat Oncol Biol PhysOct 1200872238338918793954
   PubMed Web of Science ®Google Scholar
• LaiATranANghiemphuPLPhase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiformeJournal of clinical oncology: Official journal of the American Society of Clinical Oncology [Clinical Trial, Phase II Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t] 10201129214214821135282
   PubMed Web of Science ®Google Scholar
• NarayanaAGruberDKunnakkatSA clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastomaJournal of neurosurgery. [Clinical Trial]20121162341345
   Web of Science ®Google Scholar
• ChinotOWickWMasonWOT3: Phase III trial of Bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in AVAGLIONeuro Oncology. [Abstract]2012146vi101vi105
   Google Scholar
• LaiAFilkaEMcGibbonBNghiemphuPLGrahamCYongWHPhase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerabilityInt J Radiat Oncol Biol Phys20087151372138018355978
   PubMed Web of Science ®Google Scholar
• DesjardinsAReardonDAHerndonJE2ndMarcelloJQuinnJARichJNBevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clinical cancer research: an official journal of the American Association for Cancer ResearchClinical Trial, Phase II, Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t2008142170687073
   Google Scholar
• VredenburghJJDesjardinsAHerndonJE2ndDowellJMReardonDAQuinnJAPhase II trial of bevacizumab and irinotecan in recurrent malignant gliomaClin Cancer Res2007151341253125917317837
   PubMed Web of Science ®Google Scholar
• WickWKukerWBrain edema in neurooncology: radiological assessment and managementOnkologie. [Review]2004273261266
   Google Scholar
• ChangSMParneyIFHuangWPatterns of care for adults with newly diagnosed malignant gliomaJAMA2005293555756415687310
   PubMed Web of Science ®Google Scholar
• DerrRLYeXIslasMUDesideriSSaudekCDGrossmanSAAssociation between hyperglycemia and survival in patients with newly diagnosed glioblastomaJournal of clinical oncology: official journal of the American Society of Clinical Oncology [Research Support, N.I.H., Extramural]20092771082108619139429
   PubMed Web of Science ®Google Scholar
• FriedmanHSPradosMDWenPYBevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Journal of clinical oncology: official journal of the American Society of Clinical OncologyClinical Trial, Phase II Multicenter Study, Randomized Controlled Trial. Research Support, Non-U.S. Govt2009272847334740
   Google Scholar
• VredenburghJJCloughesyTSamantMCorticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN studyThe Oncologist [Clinical Trial, Phase II Multicenter Study Randomized Controlled Trial]201015121329133421147867
   PubMed Web of Science ®Google Scholar
• NordenADYoungGSSetayeshKBevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrenceNeurology2008701077978718316689
   PubMed Web of Science ®Google Scholar
• SemradTJO’DonnellRWunTEpidemiology of venous thromboembolism in 9489 patients with malignant gliomaJ Neurosurg42007106460160817432710
   PubMed Web of Science ®Google Scholar
• BrandesAAScelziESalmistraroGErmaniMCarolloCBertiFIncidence of risk of thromboembolism during treatment high-grade gliomas: a prospective studyEur J Cancer19973310159215969389920
   PubMed Web of Science ®Google Scholar
• JenkinsEOSchiffDMackmanNKeyNSVenous thromboembolism in malignant gliomasJ Thromb Haemost220108222121719912518
   PubMed Web of Science ®Google Scholar
• MarrasLCGeertsWHPerryJRThe risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based reviewCancer200089364064610931464
   PubMed Web of Science ®Google Scholar
• DrappatzJSchiffDKesariSNordenADWenPYMedical management of brain tumor patientsNeurol Clin1120072541035107117964025
   PubMed Web of Science ®Google Scholar
• NalluriSRChuDKeresztesRZhuXWuSRisk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysisJAMANov 192008300192277228519017914
   PubMed Web of Science ®Google Scholar
• GordonMSCunninghamDManaging patients treated with bevacizumab combination therapyOncology200569 Suppl 3253316301833
   PubMed Web of Science ®Google Scholar
• NghiemphuPLGreenRMPopeWBLaiACloughesyTFSafety of anticoagulation use and bevacizumab in patients with gliomaNeuro Oncol6200810335536018436627
   PubMed Web of Science ®Google Scholar
• NordenADBartolomeoJTanakaSSafety of concurrent bevacizumab therapy and anticoagulation in glioma patientsJ NeurooncolJun 262011
   Web of Science ®Google Scholar
• VerheulHMPinedoHMPossible molecular mechanisms involved in the toxicity of angiogenesis inhibitionNat Rev Cancer20077647548517522716
   PubMed Web of Science ®Google Scholar
• EskensFAVerweijJThe clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a reviewEur J Cancer200642183127313917098419
   PubMed Web of Science ®Google Scholar
• ChamberlainMCBevacizumab plus irinotecan in recurrent glioblastomaJ Clin OncolFeb 20200826610121013 author reply 318281677
   PubMed Web of Science ®Google Scholar
• NordenADDrappatzJCiampaASColon perforation during antiangiogenic therapy for malignant gliomaNeuro Oncol2009111929925
   Web of Science ®Google Scholar
• VredenburghJJDesjardinsAHerndonJE2ndPhase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clinical cancer research: an official journal of the American Association for Cancer ResearchClinical Trial, Phase II Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’tFeb 15200713412531259
   Google Scholar
• ChamberlainMCBevacizumab and irinotecan for recurrent oligodendroglial tumorsNeurology74218120065257
   PubMed Web of Science ®Google Scholar
• SpecenierPBevacizumab in glioblastoma multiformeExpert review of anticancer therapy. [Review]2012121918
   PubMed Web of Science ®Google Scholar
• IwamotoFMAbreyLEBealKPatterns of relapse and prognosis after bevacizumab failure in recurrent glioblastomaNeurologyOct 13200973151200120619822869
   PubMed Web of Science ®Google Scholar
• BrandsmaDvan den BentMJPseudoprogression and pseudoresponse in the treatment of gliomasCurr Opin Neurol200922663363819770760
   PubMed Web of Science ®Google Scholar
• BrandesAAFranceschiETosoniAMGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patientsJ Clin Oncol200826132192219718445844
   PubMed Web of Science ®Google Scholar
• BatchelorTTSorensenAGdi TomasoEAZD2171, a panVEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsCancer Cell2007111839517222792
   PubMed Web of Science ®Google Scholar
• UllrichRBackesHLiHGlioma proliferation as assessed by 3’-fluoro-3’-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clinical cancer research: an official journal of the American Association for Cancer ResearchResearch Support, Non-U.S. Gov’t200814720492055
   Google Scholar
• ChenWCloughesyTKamdarNImaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDGJ Nucl Med200546694595215937304
   PubMed Web of Science ®Google Scholar
• ChenWDelaloyeSSilvermanDHPredicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fuorothymidine positron emission tomography: a pilot studyJ Clin Oncol200725304714472117947718
   PubMed Web of Science ®Google Scholar
• SzetoMDChakrabortyGHadleyJQuantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomasCancer research [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]20091569104502450919366800
   PubMed Web of Science ®Google Scholar
• ReardonDAGalanisEDeGrootJFClinical trial end points for high-grade glioma: the evolving landscapeNeuro-oncology. [Review]2011133353361
   PubMed Web of Science ®Google Scholar
• BatchelorTStanleyKAndersenJClinical trials in neuro-oncologyCurrent opinion in neurology. [Review]2001146689694
   Web of Science ®Google Scholar
• PradosMDSeiferheldWSandlerHMBucknerJCPhillipsTSchultzCPhase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404Int J Radiat Oncol Biol PhysMar 1520045841147115215001257
   PubMed Web of Science ®Google Scholar
• TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJournal of the National Cancer Institute. [Guideline Practice Guideline]2000923205216
   PubMed Web of Science ®Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)European Journal of Cancer. [Practice Guideline]12009452228247
   PubMed Web of Science ®Google Scholar
• WarrenKEPatronasNAikinAAAlbertPSBalisFMComparison of one-, two-, and three-dimensional measurements of childhood brain tumorsJournal of the National Cancer Institute. [Comparative Study Evaluation Studies]2001931814011405
   Google Scholar
• GalanisEBucknerJCMaurerMJValidation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methodsNeuro-oncology [Comparative Study Research Support, N.I.H., Extramural Validation Studies]2006215616516533757
   PubMed Web of Science ®Google Scholar
• WenPYMacdonaldDRReardonDAUpdated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working groupJ Clin Oncol201028111963197220231676
   PubMed Web of Science ®Google Scholar
• SorensenAGBatchelorTTWenPYZhangWTJainRKResponse criteria for gliomaNat Clin Pract Oncol200851163464418711427
   PubMedGoogle Scholar
• van den BentMJVogelbaumMAWenPYMacdonaldDRChangSMEnd point assessment in gliomas: novel treatments limit usefulness of classical Macdonald’s CriteriaJ Clin Oncol200927182905290819451418
   PubMed Web of Science ®Google Scholar
• HensonJWUlmerSHarrisGJBrain tumor imaging in clinical trialsAJNR Am J Neuroradiol200829341942418272557
   PubMed Web of Science ®Google Scholar
• CairncrossJGMacdonaldDRPexmanJHIvesFJSteroid-induced CT changes in patients with recurrent malignant gliomaNeurology19883857247263362369
   PubMed Web of Science ®Google Scholar
• CairncrossJGPexmanJHRathboneMPDelMaestroRFPostoperative contrast enhancement in patients with brain tumorAnn Neurol19851765705724026227
   PubMed Web of Science ®Google Scholar
• UlmerSBragaTABarkerFG2ndLevMHGonzalezRGHensonJWClinical and radiographic features of peritumoral infarction following resection of glioblastomaNeurology2006146791668167017101902
   PubMed Web of Science ®Google Scholar
• KumarAJLeedsNEFullerGNMalignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatmentRadiology2000217237738411058631
   PubMed Web of Science ®Google Scholar
• HyltonNDynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. Journal of clinical oncology: official journal of the American Society of Clinical OncologyReview2006242032933298
   Google Scholar
• BarrettTBrechbielMBernardoMChoykePLMRI of tumor angiogenesisJournal of magnetic resonance imaging: JMRI. [Research Support, N.I.H., Intramural Review]2007262235249
   Web of Science ®Google Scholar
• PopperlGKrethFWHermsJAnalysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?Journal of nuclear medicine: official publication, Society of Nuclear Medicine. [Controlled Clinical Trial Research Support, Non-U.S. Gov’t]2006473393403
   Web of Science ®Google Scholar
• HidaKHidaYAminDNTumor-associated endothelial cells with cytogenetic abnormalitiesCancer research. [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]2004642282498255
   Google Scholar
• CaoYZhongWSunYImprovement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistanceSeminars in cancer biology. [Research Support, Non-U.S. Gov’t Review]2009195338343
   PubMed Web of Science ®Google Scholar
• CasanovasOHicklinDJBergersGHanahanDDrug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsCancer Cell. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]200584299309
   Google Scholar
• ChamberlainMCBevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrenceNeurology2009728772773 author reply 3–419237713
   PubMed Web of Science ®Google Scholar
• ShojaeiFWuXMalikAKTumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cellsNature biotechnology2007258911920
   PubMed Web of Science ®Google Scholar
• ChamberlainMCRaizerJAntiangiogenic therapy for high-grade gliomasCNS Neurol Disord Drug Targets20098318419419601816
   PubMed Web of Science ®Google Scholar
• Paez-RibesMAllenEHudockJAntiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasisCancer Cell200915322023119249680
   PubMed Web of Science ®Google Scholar
• LamszusKKunkelPWestphalMInvasion as limitation to anti-angiogenic glioma therapyActa neurochirurgica Supplement. [Review]200388169177
   PubMedGoogle Scholar
• LefrancFBrotchiJKissRPossible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. Journal of clinical oncology: official journal of the American Society of Clinical OncologyReview2005231024112422
   Google Scholar
• NakadaMNakadaSDemuthTTranNLHoelzingerDBBerensMEMolecular targets of glioma invasionCellular and molecular life sciences: CMLS. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]2007644458478
   Google Scholar
• RubensteinJLKimJOzawaTAnti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooptionNeoplasia. [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]200024306314
   Google Scholar
• RaoJSMolecular mechanisms of glioma invasiveness: the role of proteasesNat Rev Cancer20033748950112835669
   PubMed Web of Science ®Google Scholar
• JainRKXuLalphaPlGF: a new kid on the antiangiogenesis blockCell2007131344344517981110
   PubMed Web of Science ®Google Scholar
• BergersGHanahanDModes of resistance to anti-angiogenic therapyNat Rev Cancer2008859260318650835
   PubMed Web of Science ®Google Scholar
• BrastianosPKBatchelorTTVascular endothelial growth factor inhibitors in malignant gliomasTargeted oncology. [Review]201053167174
   Web of Science ®Google Scholar
• de GrootJFFullerGKumarAJTumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and miceNeuro Oncol201012323324220167811
   PubMed Web of Science ®Google Scholar
• ZunigaRMTorcuatorRJainRRebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade gliomaJ Neurooncol201099223724220151176
   PubMed Web of Science ®Google Scholar
• QuantECNordenADDrappatzJMuzikanskyADohertyLLafrankieDRole of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumabNeuro Oncol200911555055519332770
   PubMed Web of Science ®Google Scholar
• TorcuatorRGThindRPatelMThe role of salvage reirradiation for malignant gliomas that progress on bevacizumabJ Neurooncol201097340140719838627
   PubMed Web of Science ®Google Scholar
• ReardonDAHerndonJE2ndPetersKBBevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patientsBritish journal of cancer 23201210791481148723037712
   PubMed Web of Science ®Google Scholar
• KathrynMFieldLCHelenWheelerAbstracts from the 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors, November 17–20, 2011. Orange County, California: Lot-14. A randomized phase ii study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (cabaret study)Neuro-Oncology [Abstract]2011133iii85iii91
   Google Scholar
• ChamberlainMCJohnstonSSalvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytomaJ Neurooncol200991335936718953491
   PubMed Web of Science ®Google Scholar
• RaizerJJGrimmSChamberlainMCA phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomasCancer2010116225297530520665891
   PubMed Web of Science ®Google Scholar
• ChamberlainMCJohnstonSKSalvage therapy with single agent bevacizumab for recurrent glioblastomaJournal of neuro-oncology. [Clinical Trial]2010962259269
   Web of Science ®Google Scholar
• DesjardinsAReardonDAHerndonJE2ndBevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomasClin Cancer Res200814217068707318981004
   PubMed Web of Science ®Google Scholar
• GilbertMWangMAldapeKSorensenAMikkelsonTBoksteinFRTOG 0625: a randomized Phase II trial of bevacizumab with either irinotecan (CPT) or dose-dense temozolomide (TMZ) in recurrent glioblastoma (GBM)Neuro Oncol201012
   Google Scholar
• NghiemphuPLLiuWLeeYBevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experienceNeurology200972141217122219349600
   PubMed Web of Science ®Google Scholar
• NarayanaAKellyPGolfinosJAntiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survivalJ Neurosurg2009110117318018834263
   PubMed Web of Science ®Google Scholar
• ZunigaRMTorcuatorRJainREfficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecanJ Neurooncol200991332933618953493
   PubMed Web of Science ®Google Scholar
• TaillibertSVincentLAGrangerBBevacizumab and irinotecan for recurrent oligodendroglial tumorsNeurology200972181601160619414728
   PubMed Web of Science ®Google Scholar
• HoferSElandtKGreilRClinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trialsActa oncologica. [Evaluation Studies Multicenter Study Research Support, Non-U.S. Gov’t]2011505630635
   Google Scholar
• ChauffertBFeuvretLBonnetainFRandomized multicenter phase II trial of irinotecan and bevacizumab as neoadjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma: Interim results of the TEMAVIR study from the ANOCEF groupASCO Meeting Abstracts201129152029
   Google Scholar
• HofandKFHSSørensenMSchultzHRandomized phase ii study of neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed primary glioblastoma multiformeNeuro-Oncology. [Abstract]2011133iii51
   Google Scholar
• LouEReardonDAPetersKUpfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastomaJ Clin Oncol292011 (suppl; abstr 2055)
   Web of Science ®Google Scholar
• VredenburghJJDesjardinsAReardonDAPetersKBHerndonJE2ndMarcelloJThe addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastomaClinical cancer research: an official journal of the American Association for Cancer Research201117124119412421531816
   PubMed Web of Science ®Google Scholar
• OmuroAMPBealKKarimiSCorreaDChanTADeAngelisLMPhase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM)J Clin Oncol201129152028
   Web of Science ®Google Scholar
• MacdonaldDRCascinoTLScholdSCJrCairncrossJGResponse criteria for phase II studies of supratentorial malignant gliomaJ Clin Oncol7199087127712802358840
   PubMed Web of Science ®Google Scholar
• WenPYMacdonaldDRReardonDACloughesyTFSorensenAGGalanisEUpdated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working groupJournal of clinical oncology : official journal of the American Society of Clinical Oncology201028111963177220231676
   PubMed Web of Science ®Google Scholar
• ChaSNeuroimaging in neuro-oncologyNeurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics. [Review]7200963465477
   Web of Science ®Google Scholar
• LawMYoungRJBabbJSPeccerelliNChheangSGruberMLGliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imagingRadiology. [Research Support, N.I.H., Extramural]20082472490498
   Google Scholar
• AkellaNSTwiegDBMikkelsenTAssessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial. Journal of magnetic resonance imaging : JMRIClinical Trial Clinical Trial, Phase I Multicenter Study Research Support, U.S. Gov’t, P.H.S.2004206913922
   Google Scholar
• BarajasRFJrChangJSSegalMRDifferentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imagingRadiology2009253248649619789240
   PubMed Web of Science ®Google Scholar
• SorensenAGBatchelorTTZhangWTChenPJYeoPWangMA “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patientsCancer Res200969135296530019549889
   PubMed Web of Science ®Google Scholar
• CaoYTsienCINageshVSurvival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]International journal of radiation oncology, biology, physics. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]2006643876885
   PubMed Web of Science ®Google Scholar
• GerstnerERBatchelorTTImaging and response criteria in gliomasCurrent opinion in oncology. [Research Support, Non-U.S. Gov’t Review]2010226598603
   Web of Science ®Google Scholar
• PopeWBLaiAMehtaRKimHJQiaoJYoungJRApparent diffusion coefficient histogram analysis stratifes progression-free survival in newly diagnosed bevacizumab-treated glioblastomaAJNR. [Research Support, Non-U.S. Gov’t]2011325882889
   Google Scholar
• AhluwaliaMSWenPYAntiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directionsExpert review of anticancer therapy [Editorial]201111565365621554035
   PubMed Web of Science ®Google Scholar
• EllingsonBMMalkinMGRandSDVolumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomasJournal of neuro-oncology [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]201110219510320798977
   PubMed Web of Science ®Google Scholar
• WeybrightPSundgrenPCMalyPDifferentiation between brain tumor recurrence and radiation injury using MR spectroscopyAJR200518561471147616304000
   PubMed Web of Science ®Google Scholar